Goldman Sachs Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $110
Goldman Sachs analyst Matthew Sykes initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $110.